- Home
- RRR vs APLS Comparison
RRR vs APLS Comparison
Compare RRR & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RRR
- APLS
- Stock Information
- Founded
- RRR 1976
- APLS 2009
- Country
- RRR United States
- APLS United States
- Employees
- RRR N/A
- APLS N/A
- Industry
- RRR Hotels/Resorts
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- RRR Consumer Discretionary
- APLS Health Care
- Exchange
- RRR Nasdaq
- APLS Nasdaq
- Market Cap
- RRR 3.0B
- APLS 3.3B
- IPO Year
- RRR 2016
- APLS 2017
- Fundamental
- Price
- RRR $44.86
- APLS $23.76
- Analyst Decision
- RRR Buy
- APLS Buy
- Analyst Count
- RRR 13
- APLS 18
- Target Price
- RRR $57.92
- APLS $45.53
- AVG Volume (30 Days)
- RRR 571.4K
- APLS 1.8M
- Earning Date
- RRR 05-06-2025
- APLS 05-06-2025
- Dividend Yield
- RRR 2.24%
- APLS N/A
- EPS Growth
- RRR N/A
- APLS N/A
- EPS
- RRR 2.53
- APLS N/A
- Revenue
- RRR $1,939,011,000.00
- APLS $781,367,000.00
- Revenue This Year
- RRR $2.22
- APLS $12.95
- Revenue Next Year
- RRR $2.98
- APLS $21.35
- P/E Ratio
- RRR $17.65
- APLS N/A
- Revenue Growth
- RRR 12.47
- APLS 97.02
- 52 Week Low
- RRR $42.33
- APLS $23.37
- 52 Week High
- RRR $63.29
- APLS $59.91
- Technical
- Relative Strength Index (RSI)
- RRR 43.07
- APLS 34.96
- Support Level
- RRR $42.92
- APLS $23.90
- Resistance Level
- RRR $45.89
- APLS $24.63
- Average True Range (ATR)
- RRR 1.43
- APLS 0.92
- MACD
- RRR 0.00
- APLS 0.05
- Stochastic Oscillator
- RRR 51.12
- APLS 14.94
About RRR Red Rock Resorts Inc.
Red Rock Resorts Inc along with its subsidiary is a gaming, development, and management company. The company mainly develops strategically located casino and entertainment properties. It generates a majority of its revenue from Casino.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.